
    
      This study is a single country, multicenter, observational, prospective, longitudinal cohort
      study which will include adult patients with documented history of T2DM who are initiating a
      second line oral or parenteral anti-diabetes mediation after their first line anti-diabetic
      therapy in real world setting. The follow-up period is 3 years. Patients will undergo
      clinical assessments and receive standard medical care as determined by the treating
      physician. Patients will not receive experimental intervention or experimental treatment as a
      consequence of their participation in the study.
    
  